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TheRhblood group system (ISBT004) is the secondmost important blood groupafterABOand
is the most polymorphic one, with 55 antigens encoded by 2 genes, RHD and RHCE. This
research uses next-generation sequencing (NGS) to sequence the complete RHD gene by
amplifying the whole gene using overlapping long-range polymerase chain reaction
(LR-PCR) amplicons. The aim was to study different RHD alleles present in the population to
establish reference RHD allele sequences by using the analysis of intronic single-nucleotide
polymorphisms (SNPs) and their correlation to a specific Rh haplotype. Genomic DNA
samples (n5 69) from blood donors of different serologically predicted genotypes including
R1R1 (DCe/DCe), R2R2 (DcE/DcE), R1R2 (DCe/DcE), R2RZ (DcE/DCE), R1r (DCe/dce), R2r (DcE/dce),
and R0r (Dce/dce) were sequenced and data were then mapped to the human genome
reference sequence hg38. We focused on the analysis of hemizygous samples, as these by
definition will only have a single copy of RHD. For the 69 samples sequenced, different
exonic SNPs were detected that correlate with known variants. Multiple intronic SNPs
were found in all samples: 21 intronic SNPs were present in all samples indicating their
specificity to the RHD*DAU0 (RHD*10.00) haplotype which the hg38 reference sequence
encodes. Twenty-three intronic SNPs were found to be R2 haplotype specific, and 15 were
linked to R1, R0, and RZ haplotypes. In conclusion, intronic SNPs may represent a novel
diagnostic approach to investigate known and novel variants of the RHD and RHCE genes,
while being a useful approach to establish reference RHD allele sequences.
Introduction
The Rh blood group system (ISBT004) is the second most important blood group after ABO1,2 and one
of the most polymorphic blood group systems. The RHD and the RHCE genes are located on
chromosome 1 (1p33.1_1p36) and encode the RhD protein and the RhCcEe protein, respectively.3,4
The D antigen is the most clinically significant antigen in the Rh system due to its high immunogenicity
and to being the main cause of hemolytic disease of the fetus and newborn (HDFN).5 The RHD
and the RHCE genes show 93.8% homology in their introns and coding exons.6 The similarities
between these 2 genes give an indication to their evolutionary rise from the same ancestral gene through
duplication.6-8 Recombination, deletion, and point mutations in these 2 genes generate the 8
most common Rh haplotypes, which include: R1 (DCe), R2 (DcE), R0 (Dce), RZ (DCE), r (dce), r
y (dCE),
r9 (dCe), and r0 (dcE).9
Serological testing is fast, cost-friendly, and efficient; however, it is limited by many factors: for instance,
the availability of antisera,10,11 reactivity of the antibodies, and antigen status (like weak or partial
expression). Current assignment of a partial or a weak D phenotype would require an extensive
collection of monoclonal anti-D. Monoclonals to low-frequency Rh antigens to identify specific partial
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D phenotypes are unavailable. Serological testing also leads to
prediction of the Rh genotype based on the most common haplotype
present in the population, which, for some cases, is incorrect.12
Unlike serological testing, genotyping provides the freedom to
analyze a wider range of blood antigens including low-frequency
antigens, for instance: Goa, BARC, and Tar which can cause HDFN
and alloimmunization.1 Complete blood group genotyping (BGG)
could be widely used in transfusion practice where serology fails to
clarify issues or resolve discrepancies. Extensive efforts have been
made to alternatively use molecular genotyping ranging from low
to high throughput.13 Different DNA microarray-based tests were
introduced that enable genotyping of variant blood groups by
targeting specific single-nucleotide polymorphisms (SNPs).14-19
Although these assays are very accurate, they have limitations. They
are designed to target predefined nucleotides or DNA regions
through polymerase chain reaction (PCR), whereas novel variants
remain unknown.13,20 Complete DNA sequencing could be the
most effective technique to thoroughly study blood group variations
and overcome limitations in other assays.20,21
Since it was introduced in 2005, next-generation sequencing
(NGS) has greatly impacted the genetic research field by elevating
both throughput and data generated, and at the same time lowering
significantly the cost of sequencing per nucleotide.13,14,22-24
NGS is used in HLA testing,25 which creates a strong impetus to
introduce NGS for BGG.26 Genotyping could be used to
genotype blood transfusion–dependent patients who are at risk of
alloimmunization.27-30 It could be used to genotype donors and
create a database that would make finding and recall of compatible
donors for transfusion easier.14,31-33 For these databases, refer-
ence sequences for all blood group genes are critical to allow
effective BGG.26
Different studies have aimed to use NGS in BGG using a variety of
approaches. Dezan et al,27 Chou et al,30 and Schoeman et al34
used exome sequencing to identify Rh variants but the high similarity
between the RHD and RHCE genes makes it challenging to
analyze data, especially in exons 8 and 10 where there are no
differences between the 2 genes. Hyland et al35 used long-range
PCR (LR-PCR) to amplify the RHD gene from exon 2 to exon 7 but
omitted exons 1, 8, 9, and 10. We aimed to use LR-PCR to amplify
the complete gene to get a full RHD sequence including promoter,
introns, and all exons. The aim was to achieve full RHD sequencing
to provide utility for RHD variant detection, with a follow-up in the
future of full RHCE sequencing.
Rh-associated glycoprotein gene (RHAG; ISBT030) mutations
have been linked to disturbed RhD expression.36-38 Therefore, we
also aimed to sequence the RHAG gene for samples that showed
weak D reactivity by serology and where no mutations in the RHD
gene were detected.
All samples collected in our study were tested for RHD zygosity using
droplet digital PCR (dPCR) to allow us to use a large number of
hemizygous RHD samples to unequivocally establish reference
alleles for the RHD gene. By studying intronic SNPs and their
relationship to specific Rh haplotypes, it is clear that there is a
significant difference between the R2 haplotype and other haplotypes.
Materials and methods
Sample collection and processing
Donor blood samples (n5 123) were supplied in EDTA tubes by the
National Health Service Blood and Transplant (NHSBT; Bristol,
United Kingdom). Inclusion criteria for blood samples was either their
Rh haplotype (R1, R2, R0, RZ; n5 95) or by their D reactivity (weak D;
n 5 28). Samples were serologically phenotyped for ABO, Rh, and
other blood groups by the NHSBT and were properly consented,
anonymized, and supplied with full ethical approval. Blood tubes
were centrifuged at 2500g for 10 minutes at room temperature.
Plasma on the top layer was carefully disposed and buffy coat was
collected into a 1.5-mL tube; the remaining content was discarded.
Genomic DNA extraction and zygosity testing
Genomic DNA (gDNA) was extracted from buffy coat using the
QIAamp DNA Blood Mini kit (Qiagen Ltd) following the manufac-
turer’s guidelines. gDNA concentration was determined on the
Qubit 2.0 Fluorometer (Life Technologies) using the Qubit double-
stranded DNA High Sensitivity assay kit (Life Technologies). gDNA
was finally stored at 220°C. Samples were tested for zygosity
with the aim of knowing the number of RHD alleles present for
subsequent sequence analysis. The RHD zygosity was determined
for all samples using dPCR to determine whether a sample was
Table 1. Sequence, exons covered, product sizes, and annealing temperature for primers used for RHD LR-PCR
Primer name Sequence 59-39 Exons Size, bp Annealing temperature, °C
RHD-1 forward ATCCACTTTCCACCTCCCTGC 1 10 326 62
RHD-1 reverse TCTTTGCACTTCTTCTGACAACA
RHD-2 forward CTGGGAGAGTGAAGCTGGGTGTGA 2, 3 13 709 62
RHD-2 reverse TTCATACACATCTCTACCCCCCCTC
RHD-3 forward GTTTGAGCCCAGGAGTTAGGGACCGAG 4 10 789 66
RHD-3 reverse CCCACTGTGACCACCCAGCATTCTA
RHD-4 forward CATACCTTTGAATTAAGCACTTCAC 5, 6, 7 9 895 66
RHD-4 reverse CAGAATGGCCTTTACCAGCCAT
RHD-5 forward GTTCAAGCTGTCAAGGAGACATCACTATACA 8 11 628 65
RHD-5 reverse CCAGTTTTAAGAATTTGTCGGCCGGTCG
RHD-6 forward ATACATTCCATCCAGAACTGTTCACC 9, 10 11 284 64
RHD-6 reverse AGGCCAAGAGATCCTGGTGAAACTATCC
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hemizygous (Dd) or homozygous (DD).12,39 Samples were tested
for RHD exon 5 (RHD5) and RHD exon 7 (RHD7) against the
reference gene AGO1 on chromosome 1.12,39 The droplet reader in
combination with QuantaSoft software v1.7.4 analyzed the droplet
signals and differentiated between negative and positive ones,
creating an absolute concentration of DNA. The number of RHD
copies per microliter present in a sample was compared with the
reference gene AGO1 copies per microliter.
Primer design
Six sets of primers (Table 1) were designed using the Primer3
software40 and CLC Main Workbench 9 software (Qiagen Ltd) to
amplify the RHD gene in 6 LR-PCR amplicons (Figure 1), with;1 kb
overlap between each of them. To eliminate amplification from the
RHCE gene, primers were designed around intronic differences
between the RHD and the RHCE genes positioned at the 39 end
to create RHD-specific primers. Even though exons 8 and 10 for
the RHD and the RHCE genes are identical, there are intronic
differences between the 2 genes that have been used to create
RHD-specific primers. To ensure primer specificity, primers were
assessed using Primer-BLAST on the National Center for Bio-
technology Information (NCBI) website.41 In a similar manner, 3 sets
of primers (Table 2) were designed to amplify the RHAG gene in 3
amplicons. The primers were ordered in a high-performance liquid
chromatography purified form from Eurofins Genomics.
LR-PCR optimization
To optimize PCR conditions, different annealing temperatures and
primer concentrations were tested to ensure specific amplification
from the target gene. In a 50-mL reaction, 13master mix of LongAmp
Hot Start Taq 23 Master Mix (New England Biolabs) was used with
200 ng of gDNA template; 1 mM of the forward and reverse primers
was used for all amplicons except forRHD amplicon 3, where 0.2mM
of the forward and reverse primers was used. The Veriti Thermal
Cycler (Applied Biosystems) program was set as follows: de-
naturation at 95°C for 5 minutes, 30 cycles of 95°C for 30 seconds,
annealing for 30 seconds, and extension at 65°C for 10 minutes.
Annealing temperature varied for each primer set (Tables 1 and 2).
The last extension was at 65°C for 10 minutes; finally, samples were
held at 4°C. To validate PCR amplification, PCR products were run
on a 0.7% wt/vol agarose gel in 13 Tris-acetate-EDTA buffer next to
a Quick-Load 1-kb Extend DNA Ladder (New England Biolabs).
Library construction, NGS, and data analysis
The LR-PCR products were purified using the Agencourt AMPure
XP (Beckman Coulter). Purified amplicons were then quantified
using Qubit double-stranded DNA High Sensitivity assay kit (Life
Technologies) to create an equimolar pool to ensure an equal depth
of coverage across the gene. Pooled amplicons were fragmented
using the Ion Xpress Plus Fragment Library Kit (Life Technologies)
to create a 200-base-read library and ligated to adaptors using the
Ion Xpress Barcode Adapters kit (Life Technologies) following the
manufacturer’s protocol. Size selection and library enrichment were
carried out as by Sillence et al.12 The enriched library was then
sequenced using the Ion PGM Sequencing 200 kit v2 (Life
Technologies) and the Ion Torrent PGM on a 316 chip.
Data (FASTQ) were analyzed using CLC Main Workbench 9 software
(Qiagen Ltd). Short reads were aligned to the human reference
sequence hg38 downloaded from the NCBI database.42 The RHCE

















Figure 1. The RHD and RHAG genes amplified in overlapping LR-PCR amplicons. (A) Six overlapping RHD LR-PCR amplicons. (B) Three overlapping RHAG
LR-PCR amplicons.
Table 2. Sequence, exons covered, product sizes, and annealing temperature for primers used for RHAG LR-PCR
Primer name Sequence 59-39 Exons Size, bp Annealing temperature, °C
RHAG-1 forward TGGTAGGGCTGATTTCCTTGT 6, 7, 8, 9, 10 10 003 62
RHAG-1 reverse TGGATGTTTTGGCCCAGCTT
RHAG-2 forward GCTGATCTGAGGGTTACTCCTTT 2, 3, 4, 5 10 519 62
RHAG-2 reverse AGGAGGATGGGAACGCTAAG
RHAG-3 forward AATTATTCTGCAGATTTCACCCC 1 15 083 62
RHAG-3 reverse GGAGACAAGAATTCCTCCACCTAT
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Table 3. Serologically predicted genotype, ethnicity of donors, dPCR RHD zygosity results, and RHD allele as determined by NGS for samples
sequenced (n 5 69)
Sample no. Rh serology* Ethnicity* RHD5-to-AGO1 ratio RHD7-to-AGO1 ratio dPCR RHD zygosity Allele
004_01 R1R1 Caucasian 1.12 1.05 Homozygous RHD*01
004_02 R1R1 Caucasian 1.12 1.03 Homozygous RHD*01
004_03 R1R1 Other 1.01 1.04 Homozygous RHD*01
004_04 R1R1 Caucasian 1.07 1.03 Homozygous RHD*01
004_05 R1R1 Caucasian 1.01 1.06 Homozygous RHD*01
004_06 R1R1 Caucasian 0.99 1.04 Homozygous RHD*01
004_07 R1R1 Caucasian 0.54 1.01 Discrepancy† RHD*01W.01
004_08 R1r Caucasian 0.54 0.57 Hemizygous RHD*01
004_09 R1r Caucasian 0.54 0.53 Hemizygous RHD*01
004_10 R1r Chinese 0.51 0.56 Hemizygous RHD*01
004_11 R1r Caucasian 0.53 0.54 Hemizygous RHD*01
004_12 R1r Caucasian 0.55 0.52 Hemizygous RHD*01
004_13 R1r Caucasian 0.54 0.6 Hemizygous RHD*01
004_14 R1r Caucasian 1.06 0.99 Homozygous‡ RHD*01
004_15 R1r Caucasian 0.53 0.50 Hemizygous RHD*01W.01
004_16 R1r Caucasian 0.54 0.52 Hemizygous RHD*01W.01
004_17 R1r Caucasian 0.58 0.56 Hemizygous RHD*01W.01
004_18 R1r Caucasian 0.54 0.52 Hemizygous RHD*01W.01
004_19 R1r Caucasian 0.54 0.47 Hemizygous RHD*01W.01
004_20 R1r Caucasian 0.53 0.57 Hemizygous RHD*01W.01
004_21 R1r Caucasian 0.52 0.57 Hemizygous RHD*01W.01
004_22 R1r Caucasian 0.54 0.53 Hemizygous RHD*01W.01
004_23 R1r Caucasian 0.52 0.53 Hemizygous RHD*01W.01
004_24 R1r Caucasian 0.53 0.54 Hemizygous RHD*01W.01
004_25 R1r Caucasian 0.53 0.51 Hemizygous RHD*01W.01
004_26 R1r Caucasian 0.57 0.52 Hemizygous RHD*01W.01
004_27 R1r Caucasian 0.56 0.54 Hemizygous RHD*01W.01
004_28 R1r Caucasian 0.53 0.52 Hemizygous RHD*01W.03
004_29 R1R2 Caucasian 1.09 1.03 Homozygous RHD*01
004_30 R1R2 Caucasian 0.95 0.94 Homozygous RHD*01
004_31 R1R2 Caucasian 1.08 1.05 Homozygous RHD*01
004_32 R1R2 Caucasian 0.97 1.04 Homozygous RHD*01
004_33 R1R2 Caucasian 1.03 1.08 Homozygous RHD*01
004_34 R1R2 Caucasian 0.98 1.08 Homozygous RHD*01
004_35 R1R2 Caucasian 0.46 0.51 Hemizygous§ RHD*01W.02
004_36 R1R2 Caucasian 0.51 0.51 Hemizygous§ RHD*01
004_37 R1R2 Caucasian 0.53 0.49 Hemizygous§ RHD*01
004_38 R1R2 Caucasian 0.51 0.53 Hemizygous§ RHD*01
004_39 R1R2 Caucasian 0.52 0.51 Hemizygous§ RHD*01
004_40 R1R2 Caucasian 0.53 0.52 Hemizygous§ RHD*01
The number of RHD copies per microliter present in a sample was compared with the reference gene AGO1 copies per microliter. If a sample presented a ratio of 1, it was considered
homozygous; it was considered hemizygous when present with a ratio of 0.5. Bold in the table body represents incompatible results between predicted genotype by serology and dPCR.
—, individual ethnicities not given.
*As supplied by the NHSBT, Bristol, United Kingdom.
†Sample shows discrepancy between hemizygous RHD5 and homozygous RHD7 meaning that 1 of the RHD alleles has a deletion in exon 5.
Eight samples show incompatible dPCR results with serologically predicted genotypes indicating incorrectly predicted genotypes by serology; these samples include:
‡R1r sample shows the homozygous RHD gene.
§6 R1R2 samples show the hemizygous RHD gene.
||R2R2 sample shows the hemizygous RHD gene.
{Average ratio.
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gene was masked in the RHD gene analysis by converting it into
trimmed track to prevent reads from scattering. Variant detection was
performed on a minimum coverage of 30 and variants detected were
analyzed on a single-base basis considering different parameters
including number and percentage of reads and nucleotide count.43
The reference SNP number44 was then found for each SNP detected.
Results
RHD zygosity
Samples (n5 123; Table 3) with different Rh genotypes presumed
from serology results were first tested using dPCR to determine
RHD zygosity. The presence or absence of the RHD amplification on
the dPCR platform was used to determine whether the samples were
RHD2 or RHD1, respectively. Samples showing RHD5 or RHD7 to
AGO1 ratios close to 1 were determined to be homozygous RHD1
and samples with ratios close to 0.5 were classified as hemizygous
RHD1 (Table 3). Samples included 7 R1R1 (DCe/DCe), 21 R1r
(DCe/dce), 7 R2R2 (DcE/DcE), 15 R2r (DcE/dce), 66 R1R2 (DCe/
DcE), 6 R0r (Dce/dce), and 1 R2RZ (DcE/DCE) as determined by
serology. Zygosity results were compatible with the serologically
predicted genotype except for the following samples. Sample
(004_14), previously classified by serology as being phenotypically
R1r (DCe/dce), expressed ratios of 1.06 and 0.99 for the RHD5 and
Table 3. (continued)
Sample no. Rh serology* Ethnicity* RHD5-to-AGO1 ratio RHD7-to-AGO1 ratio dPCR RHD zygosity Allele
004_41 R2R2 Caucasian 1.01 0.99 Homozygous RHD*01W.02
004_42 R2R2 Not disclosed 0.54 0.47 Hemizygous|| RHD*01W.02
004_43 R2R2 Caucasian 1.01 1.02 Homozygous RHD*01
004_44 R2R2 Caucasian 1.01 0.99 Homozygous RHD*01
004_45 R2R2 Caucasian 1.03 1.02 Homozygous RHD*01
004_46 R2R2 Caucasian 1.02 1.01 Homozygous RHD*01
004_47 R2R2 Caucasian 1.01 1 Homozygous RHD*01
004_48 R2r Caucasian 0.53 0.54 Hemizygous RHD*01
004_49 R2r Caucasian 0.53 0.51 Hemizygous RHD*01
004_50 R2r Caucasian 0.53 0.51 Hemizygous RHD*01
004_51 R2r Caucasian 0.52 0.56 Hemizygous RHD*01
004_52 R2r Caucasian 0.48 0.54 Hemizygous RHD*01
004_53 R2r Caucasian 0.53 0.47 Hemizygous RHD*01
004_54 R2r Caucasian 0.52 0.51 Hemizygous RHD*01W.02
004_55 R2r Caucasian 0.53 0.52 Hemizygous RHD*01W.02
004_56 R2r Caucasian 0.53 0.5 Hemizygous RHD*01W.02
004_57 R2r Caucasian 0.51 0.57 Hemizygous RHD*01W.02
004_58 R2r Caucasian 0.58 0.56 Hemizygous RHD*01W.02
004_59 R2r Caucasian 0.51 0.53 Hemizygous RHD*01W.02
004_60 R2r Caucasian 0.57 0.52 Hemizygous RHD*01W.02
004_61 R2r Caucasian 0.55 0.53 Hemizygous RHD*01W.02
004_62 R2r Caucasian 0.58 0.52 Hemizygous RHD*01W.02
004_63 R0r Caucasian 0.46 0.46 Hemizygous RHD*01
004_64 R0r Caucasian 0.5 0.53 Hemizygous RHD*01
004_65 R0r Caucasian 0.46 0.49 Hemizygous RHD*01
004_66 R0r Caucasian 0.49 0.52 Hemizygous RHD*01
004_67 R0r Caucasian 0.53 0.51 Hemizygous RHD*01
004_68 R0r Caucasian 0.52 0.51 Hemizygous RHD*01
004_69 R2RZ Caucasian 1.02 1.02 Homozygous RHD*01
004_70- 004_123 R1R2 — 1.0{ 1.0{ Homozygous Not sequenced
The number of RHD copies per microliter present in a sample was compared with the reference gene AGO1 copies per microliter. If a sample presented a ratio of 1, it was considered
homozygous; it was considered hemizygous when present with a ratio of 0.5. Bold in the table body represents incompatible results between predicted genotype by serology and dPCR.
—, individual ethnicities not given.
*As supplied by the NHSBT, Bristol, United Kingdom.
†Sample shows discrepancy between hemizygous RHD5 and homozygous RHD7 meaning that 1 of the RHD alleles has a deletion in exon 5.
Eight samples show incompatible dPCR results with serologically predicted genotypes indicating incorrectly predicted genotypes by serology; these samples include:
‡R1r sample shows the homozygous RHD gene.
§6 R1R2 samples show the hemizygous RHD gene.
||R2R2 sample shows the hemizygous RHD gene.
{Average ratio.
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RHD7 multiplex reactions, respectively (Table 3). This result contra-
dicted previous serological classifications and indicated that the
sample expressed 2 copies of the RHD gene. Sample (004_42),
previously classified by serology as being phenotypically R2R2,
expressed ratios of 0.54 and 0.47 for the RHD5 and RHD7multiplex
reactions, respectively (Table 3). This result contradicted previous
serological classifications and indicated that the sample expressed
1 copy of the RHD gene (hemizygous). In a similar manner, samples
004_35, 004_36, 004_37, 004_38, 004_39, and 004_40 were
previously classified by serology as being phenotypically R1R2.
However, given the ratios from the RHD5 (average 0.51) and RHD7
(average 0.51) multiplex reactions, these samples only express
1 copy of the RHD gene and are therefore classified as being RHD
hemizygous. One R1R1 sample (004_07) showed discrepancy
between hemizygous RHD5 (ratio 0.54) and homozygous RHD7
(ratio 1.01), indicating deletion of exon 5 in 1 of the RHD alleles.
NGS data
To establish referenceRHD allele sequences, we aimed to sequence
hemizygousRHD samples; nevertheless,RHD homozygous samples
were also included in the sequence analysis to detect weak D that
could be undetectable by serological testing due to the presence
of a wild-type copy of the RHD allele. We purposely included the
6 R1R2 samples (004_35, 004_36, 004_37, 004_38, 004_39,
004_40) that tested as hemizygous for the RHD gene and included
another set of 6 homozygous R1R2 samples (004_29, 004_30,
004_31, 004_32, 004_33, 004_34) for a comparison, which were
randomly chosen from the remaining 60 homozygous R1R2 samples.
Samples (n 5 69; Table 3) with different Rh serologically predicted
genotypes were sequenced on the Ion PGM, including 7 R1R1
(DCe/DCe), 21 R1r (DCe/dce), 7 R2R2 (DcE/DcE), 15 R2r (DcE/dce),
12 R1R2 (DCe/DcE), 6 R0r (Dce/dce), and 1 R2RZ (DcE/DCE). Data
were aligned to the hg38 reference sequence using CLCWorkbench
9 software (Qiagen Ltd). It is noteworthy that the RHD reference
sequence (NC_000001.11)42 is RHD*DAU0 (RHD*10.00), present-
ing a SNP in exon 8 (1136C.T), causing amino acid change
Thr379Met; therefore, all 69 samples presented a SNP in exon 8
(1136T.C) Met379Thr.
Three exonic SNPs and 519 intronic SNPs were detected across the
69 samples. Of the 28 samples that were serologically phenotyped
as weak D, 26 of them were confirmed to be weak D by NGS and the
RHD allele was determined. One R1r sample (004_28) showed a
SNP in exon 1 (8C.G) Ser3Cys that encodes weak D type 3
(RHD*01W.3). Thirteen R1r samples (004_15, 004_16, 004_17,
004_18, 004_19, 004_20, 004_21, 004_22, 004_23, 004_24,
004_25, 004_26, 004_27) and 1 R1R1 sample (004_07) showed a
SNP in exon 6, (809T.G) Val270Gly that encodes weak D type 1
(RHD*01W.1). Nine R2r samples (004_54, 004_55, 004_56,
004_57, 004_58, 004_59, 004_60, 004_61, 004_62), 2 R2R2
samples (004_41, 004_42), and 1 R1R2 sample (004_35) showed
the exon 9 (1154G.C) SNP that causes amino acid change
Gly385Ala, which encodes weak D type 2 (RHD*01W.02).
One R1r sample (004_14) and the R2RZ (004_69) sample were
serologically predicted to be weak D but no SNPs in the RHD gene
causing amino acid changes in the RhD protein were detected by
sequencing. For these 2 samples (004_14 and 004_69), the
RHAG gene was sequenced to test whether there were any
mutations in the RHAG gene that could be leading to weak D
expression. One RHAG exon 6 mutation 808G.A was detected
in sample (004_14), causing the Val270Ile change that encodes
for the RHAG*04 allele. Sample (004_69) showed a wild-type
RHAG*01 allele predicting no amino acid changes.
Intronic SNPs
Due to RHD*DAU0 (RHD*10.00) being the reference sequence
hg38, 21 homozygous SNPs were detected in all 69 samples
(Table 4) that are specific to the reference allele, that is, RHD*DAU0
(RHD*10.00). Multiple intronic SNPs are suspected to be haplotype
specific, for example, 23 SNPs (Table 5) were homozygous SNPs in
all samples with the R2 haplotype. They were detected in R2R2, R2r,
and in 3 of the 6 R1R2 samples (004_35, 004_36, 004_37), which
were determined by dPCR to be hemizygous for RHD gene. These
SNPswere also present in 6 R1R2 samples (D homozygous; 004_29,
004_30, 004_31, 004_32, 004_33, 004_34), and in the R2RZ
sample (004_69) as heterozygous SNPs.
Fifteen SNPs (Table 6) were detected as homozygous in all R1R1, R1r
and in 3 of 6 R1R2 samples (004_38, 004_39, 004_40), which were
shown by dPCR to be hemizygous for theRHD gene. They were also
detected in all 6 R0r samples (004_63, 004_64, 004_65, 004_66,
004_67, 004_68). These SNPs were also found as heterozygous
SNPs in 6 R1R2 samples (D homozygous) (004_29, 004_30,
004_31, 004_32, 004_33, 004_34), and in the R2RZ sample
(004_69). Table 7 shows the different intronic SNPs detected and
their correspondence in R2 and R1, R0, RZ RHD alleles in comparison
Table 4. Position of intronic variations and their reference SNP
number detected in all samples sequenced
Position hg38 (RHD*DAU0) All samples Location Reference SNP no.*
25 277 761 A G Intron 1 rs28661958
25 286 520 T C Intron 2 rs183024534
25 286 601 T A Intron 2 NA†
25 286 605 A T Intron 2 NA†
25 286 674 C T Intron 2 NA†
25 286 732 A G Intron 2 NA†
25 290 908 T C Intron 3 rs28521909
25 290 915 G A Intron 3 rs28562109
25 295 850 A G Intron 3 rs28451966
25 297 140 G A Intron 3 rs28786680
25 305 164 G T Intron 6 rs28703207
25 308 306 T C Intron 7 rs28374144
25 308 317 T C Intron 7 rs28719684
25 308 325 G A Intron 7 rs71493569
25 308 326 C T Intron 7 rs71493569
25 308 403 C T Intron 7 rs1801096
25 316 058 A G Intron 7 rs28453868
25 319 292 T C Intron 8 rs28397158
25 322 588 A G Intron 9 rs28435180
25 327 036 G A Intron 9 rs61777612
25 329 789 A G Intron 10 rs28654325
As the reference sequence is RHD*DAU0 (RHD*10.00), these nucleotide changes are
predicted to be RHD*DAU0 (RHD*10.00) specific.
*From the database of SNPs.44
†Not applicable. Not found in the database of SNPs.44
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with the reference sequence. From the 519 intronic SNPs detected,
most were not conserved across each haplotype (data not shown).
Most of these SNPs have been reported and show corresponding
reference numbers in the database of SNPs.44
Discussion
RHD reference sequences
We have established a methodology to fully sequence the RHD gene
including promotor, introns, and all exons that can be used to study the
different RHD alleles in the population to establish reference RHD
allele sequences. We sequenced hemizygous (1 copy) RHD genes in
samples that were confirmed to be hemizygous RHD samples by
dPCR, and compared those sequences with homozygous (2 copy)
RHD genes in samples confirmed as homozygous RHD by dPCR.
Two RHD reference sequences were submitted to GenBank and
registered with accession numbers MG944308 and MG944309
for the R1, R0, RZ haplotypes and the R2 haplotype, respectively.
We are additionally working on establishing the method for fully
sequencing the homologous RHCE gene. In many cases when
serology fails to determine an RhD variant and other platforms
cannot detect the RHD allele, follow-up work would only require
RHD sequencing to determine the exact nucleotide changes and
the RHCE gene sequencing would not be needed.
The RHD gene was fully sequenced on the Ion PGM through LR-PCR
amplification. Although LR-PCR is an efficient technique in amplifying
the gene for sequencing, the LR-PCR approach is limited. HybridRHD-
RHCE alleles or partial D alleles may not amplify if a primer position is
compromised by deletion or mutations. The RHD-specific primers in
the current study were subsequently tested with different weak and
partial D samples including: RHD*DVI.01, RHD*DNB, RHD*DIV.04,
RHD*DVII.01, DFR1, DFR2, and RHD*DIIIa (data not shown).
Amplification for all 6 PCR amplicons was achieved in all samples
except for samples with theRHD*DVI.01 allele, in which amplicon 4 did
not amplify successfully (data not shown). This issue could be resolved
in the future using a hybrid primer approach, for example, an RHD-
specific forward primer and an RHCE-specific reverse primer.
Data analysis revealed 3 exonic SNPs that encode 3 RHD alleles,
which include RHD*01W.1, RHD*01W.02, and RHD*01W.3.
Weak D type 1 RHD*01W.1 was detected in 14 samples with
R1 haplotype, whereas weak D type 2 RHD*01W.02 was found in
12 R2 haplotype samples. These results support the hypothesis that
different weak D alleles are linked to a specific haplotype, in which
weak D type 1 is linked to the R1 (DCe) haplotype, and weak D type
2 is linked to the R2 (DcE) haplotype.
45 One R1r (DCe/dce) sample
(004_28) was genotyped by NGS as weak D type 3 (RHD*01.03),
which is linked to R1 haplotype.
45
Rh haplotype-specific SNPs
Analyzing intronic SNPs (Table 7) revealed 21 homozygous SNPs
(Table 4) present in all samples sequenced. These represent SNP
variants of the RHD*DAU0 (RHD*10.00) allele, which the hg38
Table 5. Intronic SNPs present in all samples with R2 haplotype
Position SNP Location Reference SNP no.*
25 282 654 A.G Intron 1 rs3866916
25 285 089 G.A Intron 2 rs675072
25 287 909 C.G Intron 2 rs28718098
25 295 072 G.A Intron 3 rs372986392
25 295 354 C.T Intron 3 rs2904840
25 295 489 C.T Intron 3 rs190056379
25 295 708 G.A Intron 3 rs182346769
25 295 731 A.G Intron 3 rs201512625
25 295 739 G.A Intron 3 rs200682399
25 295 753 A.G Intron 3 rs143670081
25 298 980 T.C Intron 3 rs2904843
25 300 575 C.G Intron 3 rs2986167
25 305 898 A.G Intron 6 rs12126031
25 307 714 G.A Intron 7 rs2257611
25 308 845 G.C Intron 7 rs2478025
25 311 722 T.A Intron 7 rs796579065
25 316 269 A.G Intron 7 rs2427767
25 320 442 T.G Intron 8 rs3927482
25 321 858 T.C Intron 8 rs28669938
25 323 393 C.T Intron 9 rs77160738
25 323 618 G.C Intron 9 rs201304363
25 323 713 G.C Intron 9 rs202154122
25 327 668 A.G Intron 9 NA†
Intronic SNPs (hg38) and their reference SNP number were present in R2r, R2R2, R1R2,
and R2RZ samples. Intronic SNPs were present as homozygous in all 9 weak D type 2 R2r
samples, all 6 R2r samples and all 7 R2R2 samples, and in 3 of the 6 R1R2 samples that
tested as hemizygous for the RHD gene by dPCR. These SNPs were also present as
heterozygous SNPs in all 6 homozygous R1R2 samples and in the R2RZ sample.
*From the database of SNPs.44
†Not applicable. Not found in the database of SNPs.44
Table 6. Intronic SNPs present in all samples with R1, R0, and RZ
haplotypes
Position SNP Location Reference SNP no.*
25 284 544 G.C Intron 1 rs2301153
25 292 953 G.A Intron 3 rs28645510
25 295 317 G.A Intron 3 rs2986157
25 295 797 T.A Intron 3 rs2986163
25 295 800 G.A Intron 3 rs2986164
25 296 764 A.C Intron 3 rs599792
25 297 476 A.G Intron 3 rs1830962
25 298 410 G.C Intron 3 rs1293267
25 301 905 T.G Intron 5 rs28510210
25 304 945 A.T Intron 6 rs28685153
25 307 040 G.C Intron 7 rs3118453
25 311 520 G.A Intron 7 rs2478028
25 311 722 T.G Intron 7 rs796579065
25 320 257 A.C Intron 8 rs28628791
25 329 839 A.T Intron 10 rs28668998
SNPs were present as homozygous in all 6 R1R1 samples, 1 R1R1 weak D type 1
sample, all 13 R1r weak D type 1 samples, 1 R1r weak D type 3 sample, all 6 R1r samples,
6 R0r samples. These SNPs were also present as hemizygous in 3 of the 6 R1R2 samples
that tested as hemizygous for the RHD gene by dPCR. SNPs were also detected as
heterozygous SNPs in the 6 homozygous R1R2 samples and 1 R2RZ sample.
*From the database of SNPs.44
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reference sequence encodes. Some intronic SNPs were found to
be present in a specific haplotype (R2), 23 SNPs were homozygous
in all R2r, R2R2 and in 3 of the 6 R1R2 samples that tested as
hemizygous by dPCR (Table 5). They were also detected as
heterozygous SNPs in all R1R2 samples tested as homozygous by
dPCR and in the R2RZ sample. Homozygous intronic mutations
were detected in all R1R1, R1r, and in the other 3 of the 6 R1R2
samples tested as hemizygous in dPCR (Table 6). These SNPs
were also present in 6 R0r samples, and detected as heterozygous
SNPs in 6 R1R2 samples tested as homozygous by dPCR and in the
R2RZ sample. The similarities of the intronic SNPs pattern between
different haplotypes (R1, R0, and RZ) suggest that these haplotypes
might have risen from the same ancestral gene. There were no
intronic SNPs specific to each of the R1, R0, or RZ alleles.
RHAG NGS
Two samples (004_14 and 004_69) were serologically phenotyped
as weak D; however, no amino acid changes were predicted from
sequencing of the RHD gene. Different mutations in the RHAG
gene (ISBT030) have been reported that disturb the expression
of the Rh proteins.36-38 Therefore, we sequenced the RHAG gene
for these samples (004_14 and 004_69) that showed weak D
reactivity without finding any alterations in the RHD gene. Sample
(004_14) showed a SNP 808G.A in exon 6 of the RHAG gene
leading to Val270Ile that encodes the RHAG*04 allele. In this
sample, this mutation could be the main cause for the weak D
reactivity, hence no changes were detected from the sequencing of
the RHD gene in this sample to explain the weak D reactivity.
dPCR discrepant results characterized by RHD NGS
dPCR was used to test for 2 targets in the RHD gene against the
reference gene AGO1 on chromosome 1. dPCR has demonstrated
high sensitivity when used as a detection method for RHD
genotyping.12,39 All samples included in this cohort demonstrated
compatible zygosity results with the serologically predicted geno-
type except for 9 samples. Eight samples showed incompatible
Table 7. Position of intronic variations determined by NGS and their
corresponding nucleotide in R2 and R1, R0, RZ RHD alleles in
comparison with the reference sequence (hg38)
Intronic position Reference SNP no.* Intronic location hg38 R1, R0, RZ R2
25 277 761 rs28661958 Intron 1 A G G
25 282 654 rs3866916 Intron 1 A A G
25 284 544 rs2301153 Intron 1 G C G
25 285 089 rs675072 Intron 2 G G A
25 286 520 rs183024534 Intron 2 T C C
25 286 601 NA† Intron 2 T A A
25 286 605 NA† Intron 2 A T T
25 286 674 NA† Intron 2 C T T
25 286 732 NA† Intron 2 A G G
25 287 909 rs28718098 Intron 2 C C G
25 290 908 rs28521909 Intron 3 T C C
25 290 915 rs28562109 Intron 3 G A A
25 292 953 rs28645510 Intron 3 G A G
25 295 072 rs372986392 Intron 3 G G A
25 295 317 rs2986157 Intron 3 G A G
25 295 354 rs2904840 Intron 3 C C T
25 295 489 rs190056379 Intron 3 C C T
25 295 708 rs182346769 Intron 3 G G A
25 295 731 rs201512625 Intron 3 A A G
25 295 739 rs200682399 Intron 3 G G A
25 295 753 rs143670081 Intron 3 A A G
25 295 797 rs2986163 Intron 3 T A T
25 295 800 rs2986164 Intron 3 G A G
25 295 850 rs28451966 Intron 3 A G G
25 296 764 rs599792 Intron 3 A C A
25 297 140 rs28786680 Intron 3 G A A
25 297 476 rs1830962 Intron 3 A G A
25 298 410 rs1293267 Intron 3 G C G
25 298 980 rs2904843 Intron 3 T T C
25 300 575 rs2986167 Intron 3 C C G
25 301 905 rs28510210 Intron 5 T G T
25 304 945 rs28685153 Intron 6 A T A
25 305 164 rs28703207 Intron 6 G T T
25 305 898 rs12126031 Intron 6 A A G
25 307 040 rs3118453 Intron 7 G C G
25 307 714 rs2257611 Intron 7 G G A
25 308 306 rs28374144 Intron 7 T C C
25 308 317 rs28719684 Intron 7 T C C
25 308 325 rs71493569 Intron 7 G A A
25 308 326 rs71493569 Intron 7 C T T
25 308 403 rs1801096 Intron 7 C T T
25 308 845 rs2478025 Intron 7 G G C
25 311 520 rs2478028 Intron 7 G A G
25 311 722‡ rs796579065 Intron 7 T G A
25 316 058 rs28453868 Intron 7 A G G
25 316 269 rs2427767 Intron 7 A A G
Table 7. (continued)
Intronic position Reference SNP no.* Intronic location hg38 R1, R0, RZ R2
25 319 292 rs28397158 Intron 8 T C C
25 320 257 rs28628791 Intron 8 A C A
25 320 442 rs3927482 Intron 8 T T G
25 321 858 rs28669938 Intron 8 T T C
25 322 588 rs28435180 Intron 9 A G G
25 323 393 rs77160738 Intron 9 C C T
25 323 618 rs201304363 Intron 9 G G C
25 323 713 rs202154122 Intron 9 G G C
25 327 036 rs61777612 Intron 9 G A A
25 327 668 NA† Intron 9 A A G
25 329 789 rs28654325 Intron 10 A G G
25 329 839 rs28668998 Intron 10 A T A
*From the database of SNPs.44
†Not applicable. Not found in the database of SNPs.44
‡SNP position shows 3 different nucleotides: T for reference (hg38); G for R1, R0, RZ
haplotypes; and A for R2 haplotype.
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results with the predicted genotype by serological testing; they
include: 1 R1r sample (004_14), which showed the presence of
a homozygous RHD gene; 6 R1R2 samples (004_35, 004_36,
004_37, 004_38, 004_39, 004_40), which showed the presence of
a hemizygous RHD gene; and 1 R2R2 sample (004_42), which
showed as hemizygous for the RHD gene (Table 3). One R1R1
sample (004_07) showed a discrepancy between the RHD5 and
RHD7 results. Sample (004_07) presented a ratio of 0.54 for RHD5
against the reference gene AGO1, indicating a hemizygous result; a
ratio of 1.0 for RHD7 against the reference gene AGO1 indicated a
homozygous result. This discrepancy between hemizygous RHD5
and homozygous RHD7 means that 1 of the RHD alleles has a
deletion in exon 5. This gene deletion could not be detected through
the NGS due to the presence of a wild-type copy of the other RHD
allele masking the probable failed amplification of the variant allele.
The 6 R1R2 (DCe/DcE) samples, which showed only 1 copy of
the RHD gene (hemizygous), had their genotypes predicted by
serology findings based on the probability of the gene in the
population, but in these cases the genotypes are in fact less
frequent or occurring with a lower probability. These samples are
expected to be either R1r99 (DCe/dcE), RZr (DCE/dce), R2r9 (DcE/dCe),
or R0r
y (Dce/dCE) from zygosity information, which all could
be inappropriately assigned by serology as R1R2 (DCe/DcE) due to
gene frequencies in the population. Three of the R1R2 (004_35,
004_36, 004_37) samples have the intronic SNPs suspected to be
linked to the R2 haplotype and are missing all the other intronic
SNPs that are linked to the R1, R0, RZ haplotypes. Sample 004_35
was genotyped as weak D type 2, and due to the link between the
R2 haplotype and weak D type 2, this sample could only be R2r9
(DcE/dCe). The other 2 samples could also be genotyped as R2r9
(DcE/dCe) as inferred by their intronic SNP pattern. The correct
genotype of the other 3 hemizygous R1R2 samples (004_38,
004_39, 004_40) missing the R2-specific SNPs could be either
R1r0 (DCe/dcE), RZr (DCE/dce), or R0r
y (Dce/dCE). Considering
the frequency of these alleles46 in the population, in which R1r0 is
1%, RZr is 0.19%, and R0r
y is ,0.01%, it is very likely for these
samples to be R1r0 (DCe/dcE). Based on our zygosity results,
the frequency of R1r0 seems to be higher than anticipated
46 in
the population. Definitive genotypes for these samples could be
confirmed by sequencing the RHCE gene, in addition to the RHD
gene, and hence only having the RHD gene sequencing to date is a
limitation of this study. In ongoing work to sequence the RHCE
gene, multiple primer sets have been designed to amplify the gene
in LR-PCR amplicons but the regions surrounding introns 2 and 8 of
the RHCE gene are problematic. We have sequenced 35 samples
for the RHCE gene (data not shown) that had poor depth of
coverage for amplicons covering introns 2 and 8, which has made
data analysis and variant calling from these regions challenging.
Successful and robust sequencing of the RHCE gene would add to
the data set and aid identification of particular alleles in samples. It
will also be of interest to sequence the RHCE gene in samples
lacking the RHD gene, for example, rr (dce/dce) samples.
The R1r (004_14) sample that was homozygous RHD by dPCR
showed R1/R0/RZ-related SNPs and was missing all R2-related
SNPs, suggesting that the correct genotype could be R1R0
(DCe/Dce). The hemizygous R2R2 sample (004_42) was geno-
typed as weak D type 2 and showed R2-specific SNPs, therefore,
its correct genotype could only be R2r0 (DcE/dcE).
We sequenced the RHD gene in 69 samples using NGS to study
RHD mutations, assessed variations present in the population and
identified reference RHD allele sequences (Table 7). Intronic SNPs
were used to determine their relation to specific haplotypes. We
found that 21 intronic SNPs were present in all samples indicating
their specificity to the RHD*DAU0 (RHD*10.00) haplotype, which
the hg38 reference sequence encodes. Twenty-three intronic
SNPs were found to be R2 specific, and 15 were related to R1,
R0, and RZ haplotypes. In future work, we aim to identify the pattern
of intronic SNPs in the RHCE gene. Intronic SNPs may represent a
novel diagnostic approach to investigate known and novel variants
of the RHD and RHCE genes.
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